TScan Therapeutics (TCRX)

Executive Summary

TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for hematologic and solid tumor cancers. Its proprietary discovery platform enables systematic identification of novel tumor antigens and corresponding TCRs, supporting a pipeline that targets acute myeloid leukemia (AML) and HPV-positive solid tumors. The company’s lead programs, TSC-100 and TSC-101 for AML, are being evaluated in a Phase 1 trial (NCT05473910) expected to complete enrollment by mid-2026, while a separate Phase 1 study (NCT05973487) is testing multiple TCR-T candidates against HPV-related cancers including head and neck, cervical, and other solid tumors. TScan is also advancing next-generation in vivo engineering approaches to broaden the applicability of its therapies beyond ex vivo manufacturing. TScan has demonstrated initial clinical proof-of-concept with early data from its AML trial, showing potential for reduced relapse rates post stem cell transplant. The company continues to expand its solid tumor pipeline, with plans to present updated data from ongoing studies at upcoming medical meetings. With a strong cash position and a focus on scalable manufacturing, TScan is positioned to deliver catalysts over the next 12-18 months, including key efficacy readouts and potential regulatory milestones. However, as a Phase 1-stage company with no approved products, TScan faces typical development risks including clinical trial delays, competitive pressures, and financing needs.

Upcoming Catalysts (preview)

• Q3 2026Initial efficacy data from AML Phase 1 trial (TSC-100/101)75% success
• Q1 2027Interim data from HPV-positive solid tumor Phase 1 trial (multiple TSC candidates)70% success
• TBDPartnership or licensing deal for TCR-T platform or manufacturing technology50% success